• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Anti-IgE monoclonal antibodies as potential treatment in COVID-19.抗 IgE 单克隆抗体作为 COVID-19 潜在的治疗方法。
Immunopharmacol Immunotoxicol. 2021 Jun;43(3):259-264. doi: 10.1080/08923973.2021.1925906. Epub 2021 May 21.
2
What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2?在 COVID-19 或 SARS-CoV-2 无症状感染期间,皮肤科医生应该了解哪些与肥大细胞、树突状细胞、荨麻疹和奥马珠单抗相关的知识?
Dermatol Ther. 2020 Nov;33(6):e14068. doi: 10.1111/dth.14068. Epub 2020 Aug 13.
3
A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.重组人源化抗IgE单克隆抗体(奥马珠单抗)治疗中重度过敏性哮喘
Recent Pat Inflamm Allergy Drug Discov. 2007 Nov;1(3):225-31. doi: 10.2174/187221307782418900.
4
Anti-IgE treatment in allergic rhinitis.过敏性鼻炎的抗IgE治疗。
Int J Pediatr Otorhinolaryngol. 2019 Dec;127:109674. doi: 10.1016/j.ijporl.2019.109674. Epub 2019 Sep 10.
5
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.抗IgE单克隆抗体(奥马珠单抗)在治疗特应性哮喘和过敏性呼吸道疾病中的应用
Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):227-9. doi: 10.2174/1568010043343615.
6
IgE Inhibits Toll-like Receptor 7- and Toll-like Receptor 9-Mediated Expression of Interferon-α by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.IgE 通过抑制浆细胞样树突状细胞中 Toll 样受体 7 和 Toll 样受体 9 介导的干扰素-α的表达来治疗系统性红斑狼疮。
Arthritis Rheumatol. 2016 Sep;68(9):2221-31. doi: 10.1002/art.39679.
7
Omalizumab therapy for children and adolescents with severe allergic asthma.奥马珠单抗治疗儿童和青少年重度过敏性哮喘
Expert Rev Clin Immunol. 2015;11(12):1309-19. doi: 10.1586/1744666X.2015.1083860. Epub 2015 Aug 27.
8
Omalizumab may not inhibit mast cell and basophil activation in vitro.奥马珠单抗可能无法抑制体外的肥大细胞和嗜碱性粒细胞活化。
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1832-6. doi: 10.1111/jdv.12693. Epub 2014 Sep 26.
9
Targeting the FcεRI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.靶向FcεRI途径作为预防食物诱导的过敏反应的潜在策略。
Front Immunol. 2020 Dec 17;11:614402. doi: 10.3389/fimmu.2020.614402. eCollection 2020.
10
The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon RII) in patients with severe allergic asthma.奥马珠单抗治疗对重度过敏性哮喘患者低亲和力免疫球蛋白E受体(CD23/ fcεRII)的影响。
Allergy Asthma Proc. 2018 Jan 1;39(1):36-42. doi: 10.2500/aap.2018.39.4106.

引用本文的文献

1
Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study.变应原免疫治疗对过敏性鼻炎和哮喘患者预防 COVID-19 感染的保护作用:观察性、全国性、多中心研究。
JMIR Public Health Surveill. 2024 Oct 16;10:e50846. doi: 10.2196/50846.
2
Mental Healthcare in Pediatrics During the COVID-19 Pandemic: A Call for International Public Health Action.儿科心理健康保健在 COVID-19 大流行期间:呼吁国际公共卫生行动。
Adv Exp Med Biol. 2024;1458:19-34. doi: 10.1007/978-3-031-61943-4_2.
3
Early Trends to Show the Efficacy of Cordyceps militaris in Mild to Moderate COVID Inflammation.显示蛹虫草对轻至中度新冠炎症疗效的早期趋势
Cureus. 2023 Aug 18;15(8):e43731. doi: 10.7759/cureus.43731. eCollection 2023 Aug.
4
Long-Term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?慢性自发性荨麻疹患者的长期奥马珠单抗治疗:是否会增加感染 COVID-19 的风险?
Dermatol Pract Concept. 2023 Jul 1;13(3):e2023145. doi: 10.5826/dpc.1303a145.
5
Omalizumab may protect allergic patients against COVID-19: A systematic review.奥马珠单抗可能保护过敏患者预防新型冠状病毒肺炎:一项系统评价。
World Allergy Organ J. 2023 Feb;16(2):100741. doi: 10.1016/j.waojou.2023.100741. Epub 2023 Jan 9.
6
Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.慢性自发性荨麻疹患者在感染SARS-CoV-2期间安全使用奥马珠单抗。
J Cosmet Dermatol. 2023 Jan;22(1):26-27. doi: 10.1111/jocd.15544. Epub 2022 Nov 30.
7
Li-Doped Bioactive Ceramics: Promising Biomaterials for Tissue Engineering and Regenerative Medicine.锂掺杂生物活性陶瓷:用于组织工程和再生医学的有前景的生物材料。
J Funct Biomater. 2022 Sep 24;13(4):162. doi: 10.3390/jfb13040162.
8
Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.mRNA 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫在接受生物治疗的重症哮喘患者中的有效性和持久性。
Front Immunol. 2022 May 20;13:892277. doi: 10.3389/fimmu.2022.892277. eCollection 2022.
9
Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients.早期和强烈的 SARS-CoV-2 抗体反应可预测 COVID-19 患者的疾病严重程度。
J Transl Med. 2022 Apr 15;20(1):176. doi: 10.1186/s12967-022-03382-y.
10
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?治疗 COVID-19 的抗体:IgM、IgA 和双特异性抗体的新时代即将到来?
MAbs. 2022 Jan-Dec;14(1):2031483. doi: 10.1080/19420862.2022.2031483.

抗 IgE 单克隆抗体作为 COVID-19 潜在的治疗方法。

Anti-IgE monoclonal antibodies as potential treatment in COVID-19.

机构信息

Tissue Engineering and Applied Cell Sciences Department, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Tissue Engineering Department, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, Iran.

出版信息

Immunopharmacol Immunotoxicol. 2021 Jun;43(3):259-264. doi: 10.1080/08923973.2021.1925906. Epub 2021 May 21.

DOI:10.1080/08923973.2021.1925906
PMID:34018464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8146297/
Abstract

Coronavirus disease 2019 (COVID-19) is associated with irreversible effects on vital organs, especially the respiratory and cardiac systems. While the immune system plays a key role in the survival of patients to viral infections, in COVID-19, there is a hyperinflammatory immune response evoked by all the immune cells, such as neutrophils, monocytes, and includes release of various cytokines, resulting in an exaggerated immune response, named cytokine storm. This severe, dysregulated immune response causes multi-organ damage, which eventually leads to high mortality. One of the most important components of hypersensitivity is immunoglobulin E (IgE), which plays a major role in susceptibility to respiratory infections and can lead to the activation of mast cells. There is also a negative association between IgE and IFN-α, which can reduce Toll-like receptor (TLR) nine receptor expression and TLR-7 signaling to disrupt IFN production. Moreover, anti-IgE drugs such as omalizumab reduces the severity and duration of COVID-19. In addition to its anti-IgE effect, omalizumab inhibits inflammatory cells such as neutrophils. Hence, blockade of IgE may have clinical utility as an immunotherapy for COVID-19.

摘要

2019 年冠状病毒病(COVID-19)与重要器官的不可逆损伤有关,尤其是呼吸系统和心血管系统。虽然免疫系统在患者对病毒感染的存活中起着关键作用,但在 COVID-19 中,所有免疫细胞(如中性粒细胞、单核细胞)都会引发过度的炎症免疫反应,包括各种细胞因子的释放,从而导致过度的免疫反应,称为细胞因子风暴。这种严重的、失调的免疫反应导致多器官损伤,最终导致高死亡率。超敏反应的最重要组成部分之一是免疫球蛋白 E(IgE),它在呼吸道感染易感性中起主要作用,并可导致肥大细胞的激活。IgE 与 IFN-α之间也存在负相关,IFN-α 可降低 Toll 样受体(TLR)九受体的表达和 TLR-7 信号转导,从而破坏 IFN 的产生。此外,奥马珠单抗等抗 IgE 药物可降低 COVID-19 的严重程度和持续时间。奥马珠单抗除了具有抗 IgE 作用外,还能抑制中性粒细胞等炎症细胞。因此,IgE 阻断可能具有作为 COVID-19 免疫疗法的临床应用价值。